Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 136, Issue 1, 2015, Pages 112-120

  Bonneau, Claire ^a,f   Rouzier, Roman ^b   Geyl, Caroline ^c   Cortez, Annie ^d   Castela, Mathieu ^a   Lis, Raphael ^e   Daraï, Emile ^a,f   Touboul, Cyril ^a,c,g  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d HÔPITAL TENON   (France)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITÉ PARIS EST   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

Cancer associated stroma; Cancer stem cells; Chemoresistance; Cytokines; Ovarian carcinoma

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; HERMES ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CD44 PROTEIN, HUMAN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; PACLITAXEL; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LAPAROSCOPY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADJUVANT THERAPY; CANCER STAGING; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY;

ANTIGENS, CD44; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR MARKERS, BIOLOGICAL;

EID: 84925229016     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.10.024     Document Type: Article

References (39)

1. Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R, et al. Global cancer facts & figures 2007. GA: American Cancer Society; 2007.
2. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-92.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
4. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.
5. Parmar MKB, Ledermann JA, Colombo N, du Bois A, Delaloye J-F, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
6. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
7. Haute Autorité de Santé, Institut National du Cancer. Guide affection longue durée: cancer de l'ovaire; 2010.
8. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011;71:1397-412.
9. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993;14:2177-80.
10. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009;9:665-74.
11. Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 2012;59:145-55.
12. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, et al. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 2011;121:3206-19.
13. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007;117: 3660-3.
14. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005;65: 3025-9.
15. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 2009;69:9245-53.
16. Zhang S, Balch C, Chan MW, Lai H-C, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-20.
17. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U S A 2006; 103:11154-9.
18. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011;71:3991-4001.
19. Sugarbaker PH. Review of a personal experience in the management of carcinomatosis and sarcomatosis. Jpn J Clin Oncol 2001;31:573-83.
20. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359-74.
21. Wang Y-C, Yo Y-T, Lee H-Y, Liao Y-P, Chao T-K, Su P-H, et al. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 2012;180:1159-69.
22. Steffensen KD, Alvero AB, Yang Y, Waldstrøm M, Hui P, Holmberg JC, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011;2011:620523.
23. Kayastha S, Freedman AN, Piver MS, Mukkamalla J, Romero-Guittierez M, Werness BA. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res Off J Am Assoc Cancer Res 1999;5:1073-6.
24. Ricciardelli C, Rodgers RJ. Extracellular matrix of ovarian tumors. Semin Reprod Med 2006;24:270-82.
25. Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, et al. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2003;9:5318-24.
26. Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J, et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol Off J Am Soc Clin Oncol 1995;13: 1912-21.
27. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, et al. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis 2012;29:939-48.
28. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319.
29. Cordo Russo RI, García MG, Alaniz L, Blanco G, Alvarez E, Hajos SE. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer J Int Cancer 2008;122: 1012-8.
30. Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S, et al. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Lett 2007;252:225-34.
31. Bourguignon LYW, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008;283: 17635-51.
32. Gold MA,Brady WE,Lankes HA,Rose PG, Kelley JL, De Geest K, etal. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012;125:635-9.
33. Journo-Gershfeld G, Kapp D, Shamay Y, Kopeček J, David A. Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma. Pharm Res 2012;29:1121-33.
34. De Stefano I, Battaglia A, Zannoni GF, Prisco MG, Fattorossi A, Travaglia D, et al. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother Pharmacol 2011;68:107-16.
35. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 2000;10:33-41.
36. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008;100:359-72.
37. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam EE, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004;37:363-9.
38. Giridhar PV, Funk HM, Gallo CA, Porollo A, Mercer CA, Plas DR, et al. Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells. Clin Exp Metastasis 2011; 28:887-97.
39. Touboul C, Lis R, Al Farsi H, Raynaud CM, Warfa M, Althawadi H, et al. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J Transl Med 2013;11:28.